The preventive role of coenzyme Q10 and other antioxidants in injuries caused by oxidative stress

Archives of Medical Science

Volumn 3, Issue 4, 2007, Pages 305-314

  Feher, Janos ^a,b   Nemeth, Eszter ^a   Nagy, Viktor ^a   Lengyel, Gabriella ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidants; Coenzyme Q10; Lipoic acid; Omega 3 fatty acids; Oxidative stress; Selenium; Ubidecarenone; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CERIVASTATIN; CYSTEINE; HISTIDINE; METHIONINE; OMEGA 3 FATTY ACID; PHENYLALANINE; REACTIVE OXYGEN METABOLITE; RETINOL; SELENIUM; SIMVASTATIN; THIOCTIC ACID; TRYPTOPHAN; TYROSINE; UBIDECARENONE; UBIQUINONE; VITAMIN K GROUP;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROBIC METABOLISM; AGING; AMYOTROPHIC LATERAL SCLEROSIS; ARTERIOSCLEROSIS; ASTHMA; ATAXIA; BIOSYNTHESIS; BLOOD LEVEL; CARCINOGENESIS; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVITY; EPIGASTRIC PAIN; FRAGMENTATION REACTION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; HYPERTENSION; INFLAMMATION; INSOMNIA; ISCHEMIA; KIDNEY FAILURE; LIVER TRANSPLANTATION; MALE INFERTILITY; MIGRAINE; MUSCLE WEAKNESS; NAUSEA; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PAIN; PARKINSON DISEASE; PERIODONTAL DISEASE; PHOSPHORYLATION; POLYMERIZATION; PREGNANCY; RASH; REPERFUSION; RETINA MACULA DEGENERATION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; THYROID DISEASE; VISION;

EID: 38949199352     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Packer JE, Slater TF, Wilson RI. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979; 278: 737-42.
2. Pryor WA. Free radical biology: xenobiotics, cancer and aging. Ann N Y Acad Sci 1982; 393: 1-22.
3. Slater TF. Free-radical mechanism in tissue injury. Biochem J 1984; 222: 1-15.
4. Fridovich I. Biological effects of the superoxide radical. Arch Biochem Biophys 1986; 247: 1-11.
5. Feher J, Csomos G, Vereckei A. Free Radicals in Biology and Medicine. Springer-Verlag, New York 1987.
6. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987; 1: 358-64.
7. Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H. Trends in oxidative aging theories. Free Radic Biol Med 2007; 43: 477-503.
8. Bernhard D, Wang XL. Smoking, oxidative stress and cardiovascular diseases - do anti-oxidative therapies fail? Curr Med Chem 2007; 14: 1703-12.
9. Chen HI, Chang HR, Wu CY, Kao SJ, Wang D, Hsieh NK, Hsu YH. Nitric oxide in the cardiovascular and pulmonary circulation - a brief review of literatures and historical landmarks. Chin J Physiol 2007; 50: 43-50.
10. Dormandy TL. An approach to free radicals. Lancet 1983; 2: 1010-4.
11. Lieber CS. Alcohol and the liver: metabolism of ethanol, metabolic effects, and pathogenesis of injury. Acta Med Scand Suppl 1985; 703: 11-55.
12. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
13. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest 2003; 111: 769-78.
14. Shen HM, Liu ZG. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006; 40: 928-39.
15. Baez S, Segura-Aquillar J. Formation of reactive oxygen species during one-electron reduction of noradrenochrome catalyzed by NADPH-cytochrome P-45a reductase. Redox Report 1994; 1: 31-5.
16. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production from peroxynitrite: implications for endothelial injury by nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
17. Benzi G, Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med 1995; 19: 77-101.
18. Davies KJ. Protein damage and degradation by oxygen radicals. L General aspects. J BiolChem 1987; 262: 9895-901.
19. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy. A pharmaceutical perspective. J Control Release 2006; 113: 189-207.
20. Bollag W. Vitamin A and retinoids: from nutrition to pharmacotherapy in dermatology and oncology. Lancet 1983; 1: 860-3.
21. Fehér J, Láng I, Nékám K, Csomós G, Müzes G, Deák G. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease. Free Radic Res Commun 1987; 3: 373-7.
22. Beyer RE. The participation of coenzyme Q in free radical production and antioxidation. Free Radic Biol Med 1990; 8: 545-65.
23. Bors W, Heller W, Michel C, Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol 1990; 186: 343-55.
24. Chen H, Tappel AL. Protection by vitamin E, selenium, trolox C, ascorbic acid palmitate, acetylcysteine, coenzyme Q, beta-carotene, canthaxanthin, and (+)- catechin against oxidative damage to liver slices measured by oxidized heme proteins. Free Radic Biol Med 1994; 16: 437-44.
25. Hafeman DG, Sunde RA, Hoekstra WG. Effects of dietary selenium an erythrocyte and liver glutathione peroxidase in the rat. J Nutr 1974; 104: 580-7.
26. Koivistoinen P, Huttunen JK. Selenium in food and nutrition in Finland. An overview on research and action. Ann Clin Res 1986; 18: 13-7.
27. Gondi F, Pantó G, Fehér J, Bogye G, Alfthan G. Selenium in Hungary. The rock-soil-human system. Biol Trace Elem Res 1992; 35: 299-306.
28. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J Nutr 2000; 130: 2343-8.
29. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinone in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun 1990; 169: 851-7.
30. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q 10. Clin Investig 1993; 71 (8 Suppl): S116-23.
31. Bhagavan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q 10) in pediatric cardiomyopathy. Clin Nutr 2005; 24: 331-8.
32. Niki E, Tsuchiya J, Tanimura R, Kamiya Y. Regeneration of vitamin E from alpha-chromanoxyl radical by glutathione and vitamin C. Chem Lett 1982; 1: 789-92.
33. Oldfield JE. The two faces os selenium. J Nutr 1987; 117: 2002-8.
34. Sies H, Murphy ME. Role of tocopherols in the protection of biological system against oxidative damage. J Photochem Photobiol B 1991; 8: 211-24.
35. Saija A, Scalese M, Lanza M, Marzullo D, Bonina F, Castelli F. Flavonoids as antioxidant agents: importance of their interaction with biomembranes. Free Radic Biol Med 1995; 19: 481-6.
36. Feher J, Lengyel G. Nutrition and cardiovascular mortality [Hung]. Orv Hetil 2006; 147: 1491-6.
37. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care 2005; 8: 641-6.
38. Review: Alternative Medicine Review Monograph: Coenzyme Q10. 2007; 12: 159-68.
39. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50.
40. Quiles JL, Huertas JR, Mañas M, et al. Peroxidative extent and coenzyme Q levels in the rat: influence of physical training and dietary fats. Mol Aspects Med 1994; 15 (Suppl): S89-95.
41. Kitano M, Hosoe K, Fukutomi N, et al. Evaluation of the mutagenic potential of ubidecarenone using three short-term assays. Food Chem Toxicol 2006; 44: 364-70.
42. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999; 53: 764-70.
43. Folkers K, Wolaniuk A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 1985; 11: 539-45.
44. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 2003; 18: 79-89.
45. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713-5.
46. Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005; 65: 1834-6.
47. Pepping J. Coenzyme Q10. Am J Health Syst Pharm 1999; 56: 519-21.
48. Baggio E, Gandini R, Plancher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15 (Suppl): S287-94.
49. Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol 2006; 45: 282-8.
50. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician 2005; 72: 1065-70.
51. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61: 889-92.
52. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998; 95: 8892-7.
53. Ferencik M, Ebringer L. Modulatory effects of selenium and zinc on the immune system. Folia Microbiol (Praha) 2003; 48: 417-26.
54. Vadhanavikit S, Ganther HE. Selenium deficiency and decreased coenzyme Q levels. MolAspects Med 1994; 15 (Suppl): 103-7.
55. Wieland E, Schütz E, Armstrong VW, Küthe F, Heller C, Oellerich M. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solution. Transplantation 1995; 60: 444-51.
56. Zamora R, Hidalgo FJ, Tappel AL. Comparative antioxidant effectiveness of dietary beta-carotene, vitamin E, selenium and coenzyme Q10 in rat erythrocytes and plasma. J Nutr 1991; 121: 50-6.
57. Kwong LK, Kamzalov S, Rebrin I, et al. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med 2002; 33: 627-38.
58. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
59. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931-4.
60. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double blind, placebo-controlled study. J Clin Pharmacol 1993; 3: 226-9.
61. Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994; 15 (Suppl): S187-93.
62. Kaikkonen J, Nyyssönen K, Tuomainen TP, Ristonmaa U, Salonen JT. Determinants of plasma coenzyme Q10 in humans. FEBS Letters 1999; 443: 163-6.
63. De Pinieux G, Chariot P, Ammi-Saïd M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333-7.
64. Maggini M, Raschetti R, Traversa G, et al. The cerivastatin withdrawal crisis: a "post-mortem" analysis. Health Policy 2004; 69: 151-7.
65. de Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473-8.
66. Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997; 263: 67-77.
67. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999; 49: 324-9.
68. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 (Suppl): S137-44.
69. Littarru GP, Battino M, Tomasetti M, Mordente A, Santini S, Oradei A. Biochemical and clinical implications of coenzyme Q as antioxidant in plasma and in blood cellular components. Frontiers of reactive oxygen species in biology and medicine. Ed. Asada and Yoshikawa 1994; 337-40.
70. Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid composition of rat and human tissue. Lipids 1989; 24: 579-84.
71. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49: 2231-7.
72. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67: 1954-67.
73. Lee S, Gura KM, Kim S, Arsenault DA, Bistrian BR, Puder M. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract 2006; 21: 323-41.
74. Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid composition of different regions of the human brain during aging. J Neurochem 1990; 54: 415-23.
75. Loop RA, Anthony M, Willis RA, Folkers K. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. Mol Aspects Med 1994; 15 (Suppl): S195-206.
76. Satoh K, Yamato A, Nakai T, Hoshi K, Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995; 116: 1894-8.
77. Diebold BA, Bhagavan NV, Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim Biophys Acta 1994; 1200: 100-8.
78. Toescu EC, Myronova N, Verkhratsky A. Age-related structural and functional changes of brain mitochondria Cell Calcium 2000; 28: 329-38.
79. James AM, Murphy MP. How mitochondrial damage affects cell function. J Biomed Sci 2002; 9: 475-87.
80. Schon EA, Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003; 111: 303-12.
81. Nakagawa Y. Initiation of apoptotic signal by the peroxidation of cardiolipin of mitochondria. Ann N Y Acad Sci 2004; 1011: 177-84.
82. Kriska T, Korytowski W, Girotti AW. Role of mitochondrial cardiolipin peroxidation in apoptotic photokilling of 5-aminolevulinate-treated tumor cells. Arch Biochem Biophys 2005; 433: 435-46.
83. Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000; 41: 235-50.
84. Pepe S. Effect of dietary polyunsaturated fatty acids on age-related changes in cardiac mitochondrial membranes. Exp Gerontol 2005; 40: 369-76.
85. Barzanti V, Battino M, Baracca A, et al. The effect of dietary lipid changes on the fatty acid composition and function of liver, heart and brain mitochondria in the rat at different ages. Br J Nutr 1994; 71: 193-202.
86. Pepe S. Mitochondrial function in ischaemia and reperfusion of the ageing heart. Clin Exp Pharmacol Physiol 2000; 27: 745-50.
87. Furuno T, Kanno T, Arita K, et al. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 2001; 62: 1037-46.
88. Atamna H, Ames BN, Liu J. Delaying aging with mitochondrial micronutrients and antioxidants. Scientific World J 2001; 1(1 Suppl 3): 81-2.
89. Feher J, Papale A, Mannino G, Gualdi L, Balacco Gabrieli C. Mitotropic compounds for the treatment of age-related macular degeneration. The metabolic approach and a pilot study. Ophthalmologica 2003; 217: 351-7.
90. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005; 219: 154-66.
91. Chow CK, Ibrahim W, Wei Z, Chan AC. Vitamin E regulates mitochondrial hydrogen peroxide generation. Free Radic Biol Med 1999; 27: 580-7.
92. Quinn PJ, Fabisiak JP, Kagan VE. Expansion of antioxidant function of vitamin E by coenzyme Q. Biofactors 1999; 9: 149-54.
93. Kishi T, Takahashi T, Usui A, Hashizume N, Okamoto T. Cytosolic NADPH-UQ reductase, the enzyme responsible for cellular ubiquinone redox cycle as an endogenous antioxidant in the rat liver. Biof Factors 1999; 9: 189-97.
94. Giorgini E, Tommasi G, Stipa P, Tosi G, Littarru GP, Greci L. Reactivity of ubiquinones and ubiquinols with free radicals. Free Radic Res 2001; 35: 63-72.
95. Sunesen VH, Weber C, Holmer G. Lipophilic antioxidants and polyunsaturated fatty acids in lipoprotein classes: distribution and interaction. Eur J Clin Nutr 2001; 55: 115-23.
96. Kamzalov S, Sumien N, Forster MJ, Sohal RS. Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice. J Nutr 2003; 133: 3175-80.
97. Thomas SR, Leichtweis SB, Pettersson K, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 585-93.
98. Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75-82.
99. Wexler R, Aukerman G. Nonpharmacologic strategies for managing hypertension. Am Fam Physician 2006; 73: 1953-6.